• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Landsdowne Labs Names Bryan Laulicht CEO

    6/13/23 9:05:00 AM ET
    $MGTX
    $AMAG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Major Pharmaceuticals
    Health Care
    Get the next $MGTX alert in real time by email

    Company cofounder and CTO to lead button battery safety tech company toward commercialization

    The Directors of Landsdowne Labs, LLC, are pleased to announce the appointment of Bryan Laulicht to Chief Executive Officer.

    Laulicht, a company cofounder, has served as Lansdowne's Chief Technology Officer since the company's formation in 2017. He has also co-founded and served in leadership positions at two other companies focused on applying biophysics and bioengineering approaches to fulfilling unmet medical and safety needs. Both of those companies have been acquired for a combined total greater than $500M.

    Lansdowne's technology, applied to small, coin-like "button" batteries, is designed to avert injury or death when the tiny batteries--used in billions of consumer devices worldwide-- are swallowed. Studies show that every year, thousands of children and adults accidentally ingest such batteries, too often with dire results.

    Laulicht, who will assume his new position on July 3, 2023, was instrumental in developing Landsdowne's technology-- first as a post-doctoral associate in the laboratories of Robert Langer, of MIT, and of Jeffrey Karp, PhD, at Harvard, and, later, at Landsdowne.

    "Bryan Laulicht is an ideal person to lead Landsdowne toward its commercial launch," said Doug Roth, a Landsdowne Board member who is Managing Director of Investments at Connecticut Innovations (CI), a quasi-state agency that is a lead investor in the company. "Not only is Laulicht intimately familiar with the technology and the day-to-day operations of the company, but he is an experienced leader who has co-founded and built two other companies in the therapeutics, medical devices and biomaterials arenas."

    Those companies are:

    • Bullseye Therapeutics, Inc. --a Dover, Massachusetts, company providing smart injector technologies to improve the efficacy of ocular AAV Gene therapies-- acquired by Meira Gene Therapies (NASDAQ:MGTX).
    • Perosphere Pharmaceuticals, Inc. (formerly Perosphere, Inc.) -- a Danbury, Connecticut, company with a best-in-class anticoagulant reversal agent for use in life-threatening major bleeds and patients requiring urgent surgery—acquired by AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG).

    Laulicht holds a BA in Biophysics from Columbia University, a PhD in Medical Science from Brown University, and was a Postdoctoral Associate in the Harvard-MIT Division of Health Sciences and Technology.

    Laulicht said: "I look forward to furthering Landsdowne's mission to develop and commercialize our proprietary button battery safety technology platform. Our goal is to reduce the risk of severe injury or death when coin-sized batteries are accidentally swallowed."

    In a long-planned transition, on July 3, 2023, Laulicht will succeed Melissa Fensterstock, a Landsdowne co-founder who has served as CEO since 2017. Under Fensterstock's leadership, the company grew from academic concept to market-ready status through the formation of a global partnership with one of the world's largest metal and mining companies; patent approval; the winning of an NSF grant; and the raising of venture capital investment. Previously, Fensterstock worked across the life science sector--running corporate development for a small publicly traded biotechnology company; serving as a consumer product leader; and spinning out companies from Columbia and Johns Hopkins Universities. Fensterstock, who will remain involved with Landsdowne Labs in advisory and other Board capacities, will join a major "deep tech" venture fund that is based in Boston.

    Landsdowne Labs, LLC, formed in 2017, is a spinout from the laboratories of world-renowned Robert Langer at MIT and of Jeff Karp at Brigham and Women's Hospital, in Boston. The company's first product, ChildLok, is an innovative button battery technology designed to deactivate batteries following accidental ingestion, made possible by advanced material science. Landsdowne Labs is commercializing this groundbreaking technology for global companies seeking a turnkey, low-cost solution to the growing button battery health crisis. Landsdowne is headquartered in Fairfield, Conn.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20230613895741/en/

    Get the next $MGTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MGTX
    $AMAG

    CompanyDatePrice TargetRatingAnalyst
    MeiraGTx Holdings plc
    $MGTX
    7/31/2024$36.00Buy
    Chardan Capital Markets
    More analyst ratings

    $MGTX
    $AMAG
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • MeiraGTx Announces the Presentation of Four Posters at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting

      LONDON and NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage genetic medicines company, today announced the Company will exhibit four poster presentations at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting, which is being held from May 13-17, 2025, in New Orleans, LA. The posters will be available on the Posters and Publications page of the Company's website. The details of the poster presentations are below: Poster 507: An Ultra-Low Dose of a Localized CNS Gene Therapy for Severe Pediatric ObesityPoster Session: Tuesday, May 13, 6:00-7:30 pm CDTAbstract:Brain-derived neurotrophic factor (BDN

      5/13/25 4:30:00 PM ET
      $MGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • MeiraGTx Reports First Quarter 2025 Financial and Operational Results

      -  Announced strategic collaboration with Hologen AI, including a $200 million cash upfront payment to MeiraGTx and the formation of a joint venture, Hologen Neuro AI Ltd, with a further $230 million in capital committed to initially focus on expediting Phase 3 clinical development of AAV-GAD for Parkinson's disease -  U.S. Food and Drug Administration (FDA) Granted Regenerative Medicine Advanced Therapy (RMAT) designation for AAV-GAD for the treatment of Parkinson's disease -  Gained alignment with FDA on the ongoing Phase 2 AQUAx2 randomized double-blind, placebo-controlled pivotal study in Grade 2/3 radiation-induced xerostomia (RIX) to support a potential BL

      5/13/25 8:00:00 AM ET
      $MGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson's Disease

      -  This RMAT designation is based on data from 3 clinical studies demonstrating the potential benefit of AAV-GAD as a one-time treatment for Parkinson's disease -  RMAT designation includes the benefits of the Fast Track and Breakthrough Therapy designations, allows frequent regulatory interactions with the FDA, and potential routes to accelerated approval and Priority Review LONDON and NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to AAV-GAD for the t

      5/9/25 8:00:00 AM ET
      $MGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $MGTX
    $AMAG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Chardan Capital Markets resumed coverage on MeiraGTx with a new price target

      Chardan Capital Markets resumed coverage of MeiraGTx with a rating of Buy and set a new price target of $36.00

      7/31/24 6:30:53 AM ET
      $MGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $MGTX
    $AMAG
    SEC Filings

    See more
    • MeiraGTx Holdings plc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - MeiraGTx Holdings plc (0001735438) (Filer)

      6/17/25 8:08:30 AM ET
      $MGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by MeiraGTx Holdings plc

      SCHEDULE 13G/A - MeiraGTx Holdings plc (0001735438) (Subject)

      5/14/25 8:30:35 AM ET
      $MGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by MeiraGTx Holdings plc

      10-Q - MeiraGTx Holdings plc (0001735438) (Filer)

      5/13/25 8:09:19 AM ET
      $MGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $MGTX
    $AMAG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Perceptive Advisors Llc bought $5,000,000 worth of Ordinary Shares (1,250,000 units at $4.00) (SEC Form 4)

      4 - MeiraGTx Holdings plc (0001735438) (Issuer)

      8/14/24 6:54:38 PM ET
      $MGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $MGTX
    $AMAG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Yu Debra

      4 - MeiraGTx Holdings plc (0001735438) (Issuer)

      6/16/25 9:15:07 PM ET
      $MGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Shenk Thomas E

      4 - MeiraGTx Holdings plc (0001735438) (Issuer)

      6/16/25 9:13:55 PM ET
      $MGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Seligman Nicole

      4 - MeiraGTx Holdings plc (0001735438) (Issuer)

      6/16/25 9:12:17 PM ET
      $MGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $MGTX
    $AMAG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by MeiraGTx Holdings plc

      SC 13G/A - MeiraGTx Holdings plc (0001735438) (Subject)

      11/12/24 9:40:33 AM ET
      $MGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by MeiraGTx Holdings plc

      SC 13G/A - MeiraGTx Holdings plc (0001735438) (Subject)

      10/18/24 4:47:58 PM ET
      $MGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13D/A filed by MeiraGTx Holdings plc

      SC 13D/A - MeiraGTx Holdings plc (0001735438) (Subject)

      8/14/24 7:21:27 PM ET
      $MGTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care